2022
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
Han R, Yang H, Li Y, Ling C, Lu L. Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. Medical Oncology 2022, 39: 213. PMID: 36175803, PMCID: PMC9522682, DOI: 10.1007/s12032-022-01814-9.Peer-Reviewed Original ResearchConceptsProstate cancer cellsProstate cancerHDAC3 inhibitorCancer cellsCancer-related deathAnti-cancer effectsVivo mouse modelAnti-cancer efficacyAnti-cancer activityMouse modelNew agentsSecond causeHDAC inhibitorsCancerNormal cellsInhibitorsValeric acidCellsCASP3 activityCulture systemDiseaseChemosensitizers
2019
Current Approaches to Pancreatic Cancer Screening
Chhoda A, Lu L, Clerkin BM, Risch H, Farrell JJ. Current Approaches to Pancreatic Cancer Screening. American Journal Of Pathology 2019, 189: 22-35. PMID: 30558719, DOI: 10.1016/j.ajpath.2018.09.013.BooksConceptsPancreatic ductal adenocarcinomaHigh-risk individualsRisk factorsCancer syndromesHereditary breast-ovarian cancer syndromeBreast-ovarian cancer syndromeEarly resectable stagePancreatic cancer screeningScreening strategyFamilial atypical multipleCancer-related deathOvarian cancer syndromeCurrent screening strategiesLi-Fraumeni syndromePeutz-Jeghers syndromeGenetic risk factorsResectable stageCancer screeningPancreatic cancerChronic diseasesDuctal adenocarcinomaLynch syndromePrecursor lesionsLower incidenceFamilial history